Endoglin - A marker of vascular endothelial cell proliferation in cancer

Wspolczesna Onkologia

Volumn 16, Issue 1, 2012, Pages 68-71

  Kopczyńska, Ewa ^a   Makarewicz, Roman ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Endoglin (CD105); Tumor angiogenesis; Vascular endothelial cells

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD2 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER GROWTH; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; HUMAN; HYDROPHOBICITY; HYPOXIC CELL; METASTASIS; NEOPLASM; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 84858057536     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.27340     Document Type: Review

References (45)

1. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Development 1994; 8: 133-46.
2. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005; 128: 585-90.
3. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-14.
4. Heldin C, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-71. (Pubitemid 28013118)
5. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990; 265: 8361-4.
6. Lastres P, Bellon T, Cabańas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992; 22: 393-7.
7. Bellón T, Corbí A, Lastres P, et al. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993; 23: 2340-5. (Pubitemid 23265903)
8. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105): Amarker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-7. (Pubitemid 351551101)
9. Sánchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabéu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277: 43799-808. (Pubitemid 36157800)
10. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Barnabeu C, Kumar S. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003; 116: 2677-85. (Pubitemid 36857221)
11. Botella LM, Sánchez-Elsner T, Rius C, Corbí A, Bernabéu C. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 2001; 276: 34486-34494.
12. Botella LM, Sánchez-Elsner T, Sanz-Rodriguez F, et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002; 100: 4001-10. (Pubitemid 35396866)
13. Yamashita H, Ichijo H, Grimsby S, Morén A, ten Dijke P, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 1994; 269: 1995-2001. (Pubitemid 24035405)
14. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274: 584-94.
15. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002; 277: 29197-209.
16. Lastres P, Letamendía A, Zhang H, et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996; 133: 1109-21. (Pubitemid 26172515)
17. Lastres P, Martín-Perez J, Langa C, Bernabéu C. Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 1994; 301: 765-8. (Pubitemid 2118825)
18. Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P. CD105 inhibits transforming growth factor beta Smad3 signalling. Anticancer Res 2004; 24: 1337-45. (Pubitemid 38954647)
19. Lebrin F, Goumans M-J, Jonker L et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23: 4018-4028. (Pubitemid 39472423)
20. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabéu C, Vary CP. Endoglin controls cell migration and composition of focal adhesions. J Biol Chem 2004; 279: 27440-9.
21. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D, Vary CP, Bernabéu C. Endoglin regulates cytoskeletal organization through binding to ZRP-1, amember of the Lim family of proteins. J Biol Chem 2004; 279: 32858-68. (Pubitemid 39014746)
22. Jerkic M, Rivas-Elena JV, Prieto M, et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004; 18: 609-11.
23. Miller DW, Graulich W, Karges B et al. Elevated expression of endoglin, a component of the TGF-β receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999; 81: 568-72. (Pubitemid 29203054)
24. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor 1 on human vascular endothelial cells. FASEB J 1999; 14: 55-64.
25. Fonsatti E, MaioM. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Translat Med 2004; 2: 18.
26. McAllister KA, Grogg KM, Johnson DW et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-51.
27. Duff SE, Li CH, Garland JM, Kumar S.CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17: 984-92. (Pubitemid 36676386)
28. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22: 6557-63. (Pubitemid 37372335)
29. Behrem S, Zarkowić K, Eskinja N, Jonjić N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 2005; 46: 417-22. (Pubitemid 40686486)
30. Marioni G, Marino F, Giacomelli L, Staffieri C, Mariuzzi ML, Violino E, De Filippis C. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol 2006; 126: 633-9. (Pubitemid 43995216)
31. Marioni G, Giacomelli L, D'Alessandro E, Staffieri C, Guzzardo V, Staffieri A, Blandamura S. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk 1/Kdr) expression. Anticancer Res 2008; 28: 551-7. (Pubitemid 351362869)
32. Tanaka F, Otake Z, Yanagihara K et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin. Cancer Res 2001; 7: 3410-5. (Pubitemid 33069974)
33. Oxmann D, Held-Feindt J, Stark AM, Hattermann K, Yoneda T, Mentlein R. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 2008; 27: 3567-75. (Pubitemid 351793804)
34. Taskiran C, Erdem O, Onan A et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 2006; 16: 1789-93. (Pubitemid 44470037)
35. Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG, Gorter A. Expression of endoglin (CD105) in cervical cancer. Br J Cancer 2009; 100: 1617-26.
36. Saad RS, Jasnosz KM, Tung MY, Silverman JF. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 2003; 22: 248-53. (Pubitemid 36750406)
37. Salvensen HB, Gulluoglu MG, Stefansson I, Akslen LA. Significance of CD105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 2003; 111: 1011-8. (Pubitemid 37521894)
38. El-Gohary Y, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007; 127: 572-9. (Pubitemid 46587470)
39. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Modern Pathology 2004; 17: 197-203. (Pubitemid 41656516)
40. Nikiteas NI, Tzanakis N, Theodoropoulos G et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 2007; 10: 12-7. (Pubitemid 46356255)
41. Yang L, Lu W, Huang G, Wang W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 2006; 6: 110.
42. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 2007; 14: 1418-22.
43. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000; 89: 122-6. (Pubitemid 30185919)
44. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001; 7: 524-32. (Pubitemid 32707974)
45. Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, Trautwein C, Wasmuth HE, Gressner AM. Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol 2007; 19: 75h5-61.